3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasms
1
Interventions
pembrolizumab
16
Bevacizumab
12
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
Standard of Care
6
Exercise
6
Cetuximab
6
durvalumab
5
atezolizumab
5
Prednisone
5
Cyclophosphamide
5
abemaciclib
4
Paclitaxel
4
Doxorubicin
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
temsirolimus
3
enzalutamide
3
dostarlimab
3
daratumumab
3
cabozantinib
3
Sunitinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
rucaparib
×
30 days
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled